# EFTA02627739

**GLENN & EVA DUBIN REF** | Types: FULL | XRefs: 

|Field|Value|
|---|---|
|From|Karyna Shuliak <|
|To|Jeffrey <jeevacation@gmail.com <mailto:jeevacation@gmail.com»|
|Sent||
|Subject|Re: Breast cancer question|

---

**[FULL]:** From: Eva Dubin < Sent: Tuesday, January 29, 2019 5:56 PM To: Subject: Re: Breast cancer question Last combination Please note, my email address has changed to <mailto On Jan 29, 2019, at 12:41 PM, I sieevacation@gmailcom <mailto:jeevacation@gmail.com> wrote: Forwarded messa e From: Karyna Shuliak <

---

## Full Text (first 10K chars)

From: 
Eva Dubin < 
Sent: 
Tuesday, January 29, 2019 5:56 PM 
To: 
Subject: 
Re: Breast cancer question 
Last combination 
Please note, my email address has changed to 
<mailto 
On Jan 29, 2019, at 12:41 PM, I sieevacation@gmailcom <mailto:jeevacation@gmail.com>  wrote: 
 
Forwarded messa e 
From: Karyna Shuliak < 
<mailto 
Date: Tue, Jan 29, 2019 at 6:28 PM 
Subject: Re: Breast cancer question 
To: Jeffrey <jeevacation@gmail.com <mailto:jeevacation@gmail.com» 
> > 
Sorry, they just clarified: she was advised to do chemo + radiation regardless of the targeted drugs. Their 
question is which drugs to add: 
- herceptin + chemo + radiation 
- perjeta + chemo + radiation 
- herceptin+perjeta + chemo + radiation 
> On Jan 29, 2019, at 11:50 AM, Karyna Shuliak < 
> wrote: 
<mailto 
> Their treatment choices are whether to do Herceptin alone, or Perjeta alone, or both together? 
EFTA_R1_01843346 
EFTA02627739

please note 
The information contained in this communication is 
confidential, may be attorney-client privileged, may 
constitute inside information, and is intended only for 
the use of the addressee. It is the property of 
JEE 
Unauthorized use, disclosure or copying of this 
communication or any part thereof is strictly prohibited 
and may be unlawful. If you have received this 
communication in error, please notify us immediately by 
return e-mail or by e-mail to jeevacation@gmail.com <mailto:jeevacation@gmail.com> , and 
destroy this communication and all copies thereof, 
including all attachments. copyright -all rights reserved 
2 
EFTA_R1_01843347 
EFTA02627740

